Spots Global Cancer Trial Database for erlotinib hydrochloride
Every month we try and update this database with for erlotinib hydrochloride cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00661193 | Lung Cancer | carboplatin erlotinib hydro... paclitaxel | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | NCT00049101 | Colorectal Canc... | erlotinib hydro... fluorouracil leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | NCT00553462 | Lung Cancer | carboplatin erlotinib hydro... paclitaxel albu... radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | NCT03137771 | Recurrent Non-S... Stage IV Non-Sm... | 3-Dimensional C... Docetaxel Gemcitabine Intensity-Modul... Pemetrexed Diso... Stereotactic Bo... Erlotinib Hydro... Pembrolizumab | 18 Years - | NRG Oncology | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment | NCT00673569 | Lung Cancer | erlotinib hydro... gene expression... protein express... immunoenzyme te... immunologic tec... laboratory biom... needle biopsy | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma | NCT01592383 | Malignant Perit... | erlotinib hydro... | 18 Years - | University of Chicago | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung | NCT01013831 | Dysplasia Metaplasia Pulmonary Preca... | Erlotinib Hydro... Laboratory Biom... Pharmacological... | 40 Years - 79 Years | National Cancer Institute (NCI) | |
| Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | NCT00049101 | Colorectal Canc... | erlotinib hydro... fluorouracil leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer | NCT00614653 | Pancreatic Canc... | Bevacizumab Erlotinib Capecitabine Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Erlotinib in Combination With Bortezomib | NCT00895687 | Advanced Cancer | Erlotinib Hydro... Bortezomib | - | M.D. Anderson Cancer Center | |
| Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma | NCT01103375 | Adult Anaplasti... Adult Anaplasti... Adult Diffuse A... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Oligodend... Recurrent Adult... | erlotinib hydro... isotretinoin laboratory biom... protein express... | 18 Years - | Wake Forest University Health Sciences | |
| Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | NCT00390429 | Lung Cancer Unspecified Adu... | docetaxel erlotinib hydro... | 18 Years - | University of California, Davis | |
| MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | NCT01294306 | Adenosquamous L... Bronchioloalveo... Large Cell Lung... Lung Adenocarci... Recurrent Non-S... Squamous Cell L... | Akt Inhibitor M... Erlotinib Hydro... Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | NCT00039494 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | erlotinib hydro... 3-dimensional c... temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00274833 | CNS Tumor, Adul... | erlotinib hydro... temozolomide radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Celecoxib and Erlotinib in Treating Patients With Liver Cancer | NCT00293436 | Liver Cancer | celecoxib erlotinib hydro... adjuvant therap... | 18 Years - | University of California, San Francisco | |
| MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | NCT00769483 | Pancreatic Canc... Pancreatic Aden... | MK-0646 Gemcitabine Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer | NCT00054275 | Breast Cancer | docetaxel erlotinib hydro... | 18 Years - | Case Comprehensive Cancer Center | |
| Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) | NCT00826449 | Lung Cancer Non-Small Cell ... | Dasatinib Erlotinib | 16 Years - | M.D. Anderson Cancer Center | |
| Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | NCT02273362 | Cirrhosis Hepatocellular ... | Erlotinib Erlotinib Hydro... Laboratory Biom... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | NCT02273362 | Cirrhosis Hepatocellular ... | Erlotinib Erlotinib Hydro... Laboratory Biom... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix | NCT00031993 | Cervical Squamo... Recurrent Cervi... | erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer | NCT00739063 | Breast Cancer | Tarceva | - | M.D. Anderson Cancer Center | |
| Celecoxib and Erlotinib in Treating Patients With Liver Cancer | NCT00293436 | Liver Cancer | celecoxib erlotinib hydro... adjuvant therap... | 18 Years - | University of California, San Francisco | |
| Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | NCT01064479 | Metastatic Squa... Metastatic Squa... Metastatic Squa... Metastatic Squa... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph... | Carboplatin Cisplatin Docetaxel Erlotinib Hydro... Laboratory Biom... Pharmacological... Placebo Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Erlotinib in Combination With Bortezomib | NCT00895687 | Advanced Cancer | Erlotinib Hydro... Bortezomib | - | M.D. Anderson Cancer Center | |
| WBRT & Erlotinib in Advanced NSCLC and Brain Metastases | NCT00554775 | Lung Cancer Metastatic Canc... | erlotinib hydro... placebo | 18 Years - | University College, London | |
| Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer. | NCT00611715 | Breast Cancer | erlotinib hydro... letrozole fluorescence in... immunohistochem... laboratory biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Study of Erlotinib in Combination With Dasatinib | NCT00895128 | Advanced Cancer | Erlotinib Hydro... Dasatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane | NCT00059852 | Breast Cancer | erlotinib hydro... gemcitabine hyd... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection | NCT00087269 | Stage IA Non-sm... Stage IB Non-sm... Stage IIA Non-s... Stage IIB Non-s... Stage IIIA Non-... | erlotinib hydro... therapeutic end... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | NCT00387322 | Lung Cancer Unspecified Adu... | erlotinib hydro... pemetrexed diso... | 18 Years - | University of California, Davis | |
| Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer | NCT00266097 | Extrahepatic Bi... Gallbladder Can... Pancreatic Canc... | erlotinib hydro... gemcitabine hyd... oxaliplatin radiation thera... gemcitabine hyd... Oxaliplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | NCT00217529 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | pegfilgrastim carboplatin docetaxel erlotinib hydro... | 18 Years - | Fred Hutchinson Cancer Center | |
| Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer | NCT00955695 | Lung Cancer | erlotinib hydro... gefitinib questionnaire a... quality-of-life... whole-brain rad... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer | NCT00063947 | Adenocarcinoma ... Recurrent Pancr... Stage II Pancre... Stage III Pancr... | erlotinib hydro... gemcitabine hyd... radiation thera... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer | NCT00733408 | Estrogen Recept... HER2-negative B... Progesterone Re... Recurrent Breas... Stage IV Breast... Triple-negative... | paclitaxel albu... bevacizumab erlotinib hydro... | - | University of Washington | |
| Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC | NCT00283244 | Lung Cancer | erlotinib hydro... gemcitabine hyd... | 70 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center | |
| ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA) | NCT00313560 | Pancreatic Canc... | erlotinib hydro... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer | NCT00030485 | Endometrial Can... | erlotinib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck | NCT00063895 | Recurrent Non-s... Recurrent Ovari... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IIIA Non-... Stage IIIA Ovar... Stage IIIB Non-... Stage IIIB Ovar... Stage IIIC Ovar... Stage IV Non-sm... Stage IV Ovaria... Stage IV Squamo... Stage IV Squamo... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... | erlotinib hydro... pharmacological... pharmacogenomic... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | NCT01259089 | Adenocarcinoma ... Non-small Cell ... | erlotinib hydro... Hsp90 inhibitor... laboratory biom... needle biopsy mutation analys... pharmacological... | 18 Years - | Northwestern University | |
| Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | NCT02926638 | MET Positive Recurrent Squam... Stage IV Squamo... | Erlotinib Hydro... Laboratory Biom... Rilotumumab | 18 Years - | SWOG Cancer Research Network | |
| Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer | NCT00088946 | Bladder Cancer | Polyphenon E erlotinib hydro... Erlotinib place... Polyphenon E | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00410826 | Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... | erlotinib hydro... cisplatin 3-dimensional c... intensity-modul... quality-of-life... | 18 Years - | University of Washington | |
| Erlotinib in Combination With Pralatrexate in Advanced Malignancies | NCT01532011 | Advanced Cancer... Solid Tumors | Erlotinib Pralatrexate | 12 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Combination With Cetuximab | NCT00895362 | Advanced Cancer... | Erlotinib Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer | NCT00281866 | Head and Neck C... | erlotinib hydro... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer | NCT01866410 | Recurrent Non-S... Stage IV Non-Sm... | Cabozantinib S-... Erlotinib Hydro... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | NCT00126581 | Lung Adenocarci... Lung Adenosquam... Malignant Peric... Malignant Pleur... Minimally Invas... Stage IIIB Lung... Stage IV Lung N... | Carboplatin Erlotinib Erlotinib Hydro... Paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | NCT00499655 | Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm... | erlotinib hydro... celecoxib placebo laboratory biom... immunohistochem... fluorescence in... mutation analys... protein express... gene expression... | 18 Years - | City of Hope Medical Center | |
| Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer | NCT01857271 | Stage IIIA Non-... Stage IIIB Non-... | Erlotinib Hydro... Therapeutic Con... Laboratory Biom... | 18 Years - | Albert Einstein College of Medicine | |
| Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer | NCT00088946 | Bladder Cancer | Polyphenon E erlotinib hydro... Erlotinib place... Polyphenon E | 18 Years - | Jonsson Comprehensive Cancer Center | |
| A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer | NCT00060411 | Mucinous Adenoc... Mucinous Adenoc... Recurrent Colon... Recurrent Recta... Signet Ring Ade... Signet Ring Ade... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... | erlotinib hydro... fluorouracil leucovorin calc... oxaliplatin bevacizumab | 18 Years - | National Cancer Institute (NCI) | |
| Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00079053 | Head and Neck C... | erlotinib hydro... adjuvant therap... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery | NCT00242502 | Hepatocellular ... Liver Cancer | Bevacizumab (Av... Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer | NCT00266097 | Extrahepatic Bi... Gallbladder Can... Pancreatic Canc... | erlotinib hydro... gemcitabine hyd... oxaliplatin radiation thera... gemcitabine hyd... Oxaliplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers | NCT01344824 | Lung Cancer | bevacizumab carboplatin erlotinib hydro... pemetrexed diso... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer | NCT00042835 | Adenocarcinoma ... Bronchoalveolar... Large Cell Lung... Squamous Cell L... Stage IIIA Non-... Stage IIIB Non-... | cisplatin etoposide erlotinib hydro... radiation thera... docetaxel paclitaxel carboplatin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery | NCT00254384 | Recurrent Lung ... Stage IA Lung N... Stage IB Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIB Lung... | Cisplatin Docetaxel Erlotinib Erlotinib Hydro... Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck | NCT00720304 | Head and Neck C... | docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00778167 | Recurrent Non-s... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-sm... | cixutumumab erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors | NCT00045201 | Adult Solid Neo... | Erlotinib Hydro... Irinotecan Hydr... | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | NCT00553462 | Lung Cancer | carboplatin erlotinib hydro... paclitaxel albu... radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | NCT01064479 | Metastatic Squa... Metastatic Squa... Metastatic Squa... Metastatic Squa... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph... | Carboplatin Cisplatin Docetaxel Erlotinib Hydro... Laboratory Biom... Pharmacological... Placebo Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center | |
| RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | NCT01193881 | Recurrent Non-S... Stage IV Non-Sm... | Erlotinib Hydro... Gamma-Secretase... Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection | NCT01927744 | Head and Neck C... | Docetaxel Erlotinib Placebo Questionnaires Phone Call Chemotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery | NCT01688973 | Recurrent Renal... Stage III Renal... Stage IV Renal ... Type 1 Papillar... Type 2 Papillar... | Erlotinib Hydro... Laboratory Biom... Tivantinib | - | National Cancer Institute (NCI) | |
| MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | NCT00769483 | Pancreatic Canc... Pancreatic Aden... | MK-0646 Gemcitabine Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | NCT00039494 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | erlotinib hydro... 3-dimensional c... temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer | NCT00881751 | Liver Cancer | bevacizumab erlotinib hydro... sorafenib tosyl... | 18 Years - 116 Years | Medical University of South Carolina | |
| Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors | NCT00356889 | Cholangiocarcin... Cholangiocarcin... Gastrointestina... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | erlotinib hydro... bevacizumab | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | NCT01013649 | Pancreatic Aden... Pancreatic Duct... Pancreatic Intr... Stage I Pancrea... Stage II Pancre... | 3-Dimensional C... Biospecimen Col... Capecitabine Chemotherapy Computed Tomogr... Erlotinib Hydro... Fluorouracil Gemcitabine Hyd... Intensity-Modul... Magnetic Resona... Quality-of-Life... X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer | NCT00749892 | Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage 0a Bladde... Stage 0a Renal ... Stage 0a Ureter... Stage 0a Urethr... Stage 0is Bladd... Stage 0is Renal... Stage 0is Urete... Stage 0is Ureth... Stage II Bladde... Stage II Renal ... Stage II Ureter... Stage II Urethr... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... | Erlotinib Hydro... | 19 Years - | M.D. Anderson Cancer Center | |
| Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer | NCT00091026 | Adenocarcinoma ... Recurrent Pancr... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | cetuximab gemcitabine hyd... bevacizumab erlotinib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib | NCT01432119 | Advanced Cancer... | SIR-Spheres Cetuximab Erlotinib Break-Through S... | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma | NCT00353301 | Renal Cell Carc... | Erlotinib hydro... Sirolimus | 18 Years - | University of Colorado, Denver | |
| Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction | NCT00047346 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | erlotinib hydro... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
